
Guardant Health (GH) | Stock Overview & Key Data
Guardant Health Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: $181.07 on February 8, 2021
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Financial Highlights
Profitability
Returns and Earnings
Growth
Peer Performance Comparison
Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
---|---|---|---|---|---|---|---|---|---|
Guardant Health GH | 6.76B Mid-cap | 30.93% | 6.71% | 30.11% | 22.14% | 70.70% | 87.00% | 0.09% | -36.54% |
Thermo Fisher TMO | 173.97B Large-cap | -0.50% | 8.11% | 12.16% | -16.67% | -11.84% | -22.72% | -23.62% | 11.35% |
Danaher DHR | 143.61B Large-cap | 1.76% | -0.06% | 2.95% | -1.44% | -12.73% | -25.19% | -24.02% | 10.43% |
Exact Sciences EXAS | 7.76B Mid-cap | -14.18% | -23.44% | -22.75% | -21.74% | -28.00% | -28.10% | -4.03% | -51.96% |
Charles River CRL | 7.37B Mid-cap | -10.89% | -6.09% | 5.22% | -6.97% | -18.56% | -25.99% | -36.17% | -30.65% |
RadNet RDNT | 4.10B Mid-cap | -2.43% | -3.54% | -5.36% | -14.42% | -23.93% | -15.07% | 139.93% | 209.87% |
Ownership & Short Interest
Guardant Health Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Guardant Health would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is GH's 52-week high and low?
- In the last 52 weeks, Guardant Health reached a high of $54.62 (on August 8, 2025) and a low of $20.14 (on October 25, 2024).
- What is the market cap and P/E ratio for GH?
- Curious about Guardant Health's size and valuation? Its market capitalization stands at 6.76B. When it comes to valuation, the P/E ratio (trailing twelve months) is -15.23, and the forward P/E (looking ahead) is -20.01.
- Does GH pay dividends? If so, what's the yield?
- As for dividends, Guardant Health isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Guardant Health's main competitors or similar companies to consider before investing?
When looking at Guardant Health, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Thermo Fisher
TMO173.97B Healthcare Diagnostics & Research -22.72% -23.62% Danaher
DHR143.61B Healthcare Diagnostics & Research -25.19% -24.02% Exact Sciences
EXAS7.76B Healthcare Diagnostics & Research -28.10% -4.03% Charles River
CRL7.37B Healthcare Diagnostics & Research -25.99% -36.17% RadNet
RDNT4.10B Healthcare Diagnostics & Research -15.07% 139.93% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Guardant Health Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Guardant Health's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 312.48%, the Debt to Equity ratio from the most recent quarter is -4.37, and its Gross Profit Margin stands at 65.01%.
- What is the recent revenue and earnings growth for GH?
- Looking at Guardant Health's growth, its revenue over the trailing twelve months (TTM) was $829M. Compared to the same quarter last year (YoY), quarterly revenue grew by 30.90%, and quarterly earnings saw a YoY growth of 30.95%.
- How much of GH stock is held by insiders and institutions?
- Wondering who owns Guardant Health stock? Company insiders (like executives and directors) hold about 4.50% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 99.29%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.